Moreover, our proof-of-principle study focused on the driver mutations BRAF and NRAS, which account for up to 70% of melanomas, and are well suited to this purpose because of the low likelihood of clonal diversity with trunk mutations such as these in melanoma. Here, NRAS is linked to melanoma.